Betta Pharmaceuticals Co Ltd
300558
Company Profile
Business description
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Contact
No. 355, Xingzhong Road
Economic and Technological Development Zone
Yuhang District, Zhejiang Province
Hangzhou311100
CHNT: +86 57189265665
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,696
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.80 | 106.80 | 1.20% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,902.53 | 169.08 | 0.68% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
| NZX 50 Index | 12,853.58 | 23.46 | -0.18% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
| SSE Composite Index | 3,617.60 | 34.29 | 0.96% |